{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Pleomorphic+Liposarcoma&page=2",
    "query": {
      "condition": "Pleomorphic Liposarcoma",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Pleomorphic+Liposarcoma&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-05-22T01:40:02.716Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04979442",
      "title": "Treatment of Milademetan Versus Trabectedin in Patient With Dedifferentiated Liposarcoma",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Dedifferentiated Liposarcoma"
      ],
      "interventions": [
        {
          "name": "RAIN-32",
          "type": "DRUG"
        },
        {
          "name": "Trabectedin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Rain Oncology Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 175,
      "start_date": "2021-07-14",
      "completion_date": "2023-10-01",
      "has_results": true,
      "last_update_posted_date": "2025-01-14",
      "last_synced_at": "2026-05-22T01:40:02.716Z",
      "location_count": 22,
      "location_summary": "Palo Alto, California • Santa Monica, California • Aurora, Colorado + 16 more",
      "locations": [
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Santa Monica",
          "state": "California"
        },
        {
          "city": "Santa Monica",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04979442"
    },
    {
      "nct_id": "NCT03009201",
      "title": "Ribociclib and Doxorubicin in Treating Patients With Metastatic or Advanced Soft Tissue Sarcomas That Cannot Be Removed by Surgery",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Soft Tissue Sarcoma",
        "Locally Advanced Angiosarcoma",
        "Locally Advanced Leiomyosarcoma",
        "Locally Advanced Liposarcoma",
        "Locally Advanced Malignant Peripheral Nerve Sheath Tumor",
        "Locally Advanced Myxofibrosarcoma",
        "Locally Advanced Undifferentiated Pleomorphic Sarcoma",
        "Metastatic Angiosarcoma",
        "Metastatic Epithelioid Sarcoma",
        "Metastatic Fibrosarcoma",
        "Metastatic Liposarcoma",
        "Metastatic Malignant Peripheral Nerve Sheath Tumor",
        "Metastatic Myxofibrosarcoma",
        "Metastatic Soft Tissue Sarcoma",
        "Metastatic Synovial Sarcoma",
        "Metastatic Undifferentiated Pleomorphic Sarcoma",
        "Myxofibrosarcoma",
        "Pleomorphic Rhabdomyosarcoma",
        "Stage III Soft Tissue Sarcoma AJCC v7",
        "Stage IV Soft Tissue Sarcoma AJCC v7",
        "Undifferentiated (Embryonal) Sarcoma",
        "Unresectable Leiomyosarcoma",
        "Unresectable Liposarcoma",
        "Unresectable Malignant Peripheral Nerve Sheath Tumor",
        "Unresectable Soft Tissue Sarcoma",
        "Unresectable Synovial Sarcoma",
        "Unresectable Undifferentiated Pleomorphic Sarcoma"
      ],
      "interventions": [
        {
          "name": "Doxorubicin Hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Pharmacological Study",
          "type": "OTHER"
        },
        {
          "name": "Ribociclib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "OHSU Knight Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 16,
      "start_date": "2017-03-10",
      "completion_date": "2023-06-30",
      "has_results": false,
      "last_update_posted_date": "2023-08-16",
      "last_synced_at": "2026-05-22T01:40:02.716Z",
      "location_count": 1,
      "location_summary": "Portland, Oregon",
      "locations": [
        {
          "city": "Portland",
          "state": "Oregon"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03009201"
    },
    {
      "nct_id": "NCT04420975",
      "title": "Nivolumab and BO-112 Before Surgery for the Treatment of Resectable Soft Tissue Sarcoma",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Leiomyosarcoma",
        "Malignant Peripheral Nerve Sheath Tumor",
        "Myxofibrosarcoma",
        "Pleomorphic Rhabdomyosarcoma",
        "Resectable Dedifferentiated Liposarcoma",
        "Resectable Soft Tissue Sarcoma",
        "Resectable Undifferentiated Pleomorphic Sarcoma",
        "Soft Tissue Fibrosarcoma",
        "Spindle Cell Sarcoma",
        "Stage I Retroperitoneal Sarcoma AJCC (American Joint Committee on Cancer) v8",
        "Stage I Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8",
        "Stage IA Retroperitoneal Sarcoma AJCC v8",
        "Stage IA Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8",
        "Stage IB Retroperitoneal Sarcoma AJCC v8",
        "Stage IB Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8",
        "Stage II Retroperitoneal Sarcoma AJCC v8",
        "Stage II Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8",
        "Stage III Retroperitoneal Sarcoma AJCC v8",
        "Stage III Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8",
        "Stage IIIA Retroperitoneal Sarcoma AJCC v8",
        "Stage IIIA Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8",
        "Stage IIIB Retroperitoneal Sarcoma AJCC v8",
        "Stage IIIB Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8",
        "Storiform-Pleomorphic Malignant Fibrous Histiocytoma",
        "Synovial Sarcoma",
        "Undifferentiated High Grade Pleomorphic Sarcoma of Bone",
        "Undifferentiated Pleomorphic Sarcoma",
        "Undifferentiated Pleomorphic Sarcoma With Osteoclast-Like Giant Cells",
        "Undifferentiated Pleomorphic Sarcoma, Inflammatory Variant",
        "Undifferentiated Spindle Cell Sarcoma"
      ],
      "interventions": [
        {
          "name": "Definitive Surgical Resection",
          "type": "PROCEDURE"
        },
        {
          "name": "Nanoplexed Poly I:C BO-112",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Nivolumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Radiation Therapy",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "BIOLOGICAL",
        "RADIATION"
      ],
      "sponsor": "Jonsson Comprehensive Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 14,
      "start_date": "2020-10-14",
      "completion_date": "2028-01-31",
      "has_results": false,
      "last_update_posted_date": "2026-03-10",
      "last_synced_at": "2026-05-22T01:40:02.716Z",
      "location_count": 1,
      "location_summary": "Los Angeles, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04420975"
    },
    {
      "nct_id": "NCT00720174",
      "title": "Cixutumumab and Doxorubicin Hydrochloride in Treating Patients With Unresectable, Locally Advanced, or Metastatic Soft Tissue Sarcoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Adult Angiosarcoma",
        "Adult Desmoplastic Small Round Cell Tumor",
        "Adult Epithelioid Sarcoma",
        "Adult Extraskeletal Myxoid Chondrosarcoma",
        "Adult Extraskeletal Osteosarcoma",
        "Adult Fibrosarcoma",
        "Adult Leiomyosarcoma",
        "Adult Liposarcoma",
        "Adult Malignant Mesenchymoma",
        "Adult Malignant Peripheral Nerve Sheath Tumor",
        "Adult Rhabdomyosarcoma",
        "Adult Synovial Sarcoma",
        "Adult Undifferentiated High Grade Pleomorphic Sarcoma of Bone",
        "Childhood Angiosarcoma",
        "Childhood Desmoplastic Small Round Cell Tumor",
        "Childhood Epithelioid Sarcoma",
        "Childhood Fibrosarcoma",
        "Childhood Leiomyosarcoma",
        "Childhood Liposarcoma",
        "Childhood Malignant Mesenchymoma",
        "Childhood Malignant Peripheral Nerve Sheath Tumor",
        "Childhood Pleomorphic Rhabdomyosarcoma",
        "Childhood Rhabdomyosarcoma With Mixed Embryonal and Alveolar Features",
        "Childhood Synovial Sarcoma",
        "Dermatofibrosarcoma Protuberans",
        "Malignant Adult Hemangiopericytoma",
        "Malignant Childhood Hemangiopericytoma",
        "Metastatic Childhood Soft Tissue Sarcoma",
        "Previously Treated Childhood Rhabdomyosarcoma",
        "Recurrent Adult Soft Tissue Sarcoma",
        "Recurrent Childhood Rhabdomyosarcoma",
        "Recurrent Childhood Soft Tissue Sarcoma",
        "Stage III Adult Soft Tissue Sarcoma",
        "Stage IV Adult Soft Tissue Sarcoma",
        "Untreated Childhood Rhabdomyosarcoma"
      ],
      "interventions": [
        {
          "name": "Cixutumumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Doxorubicin Hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG",
        "OTHER"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "16 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "16 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2008-06",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2016-05-17",
      "last_synced_at": "2026-05-22T01:40:02.716Z",
      "location_count": 13,
      "location_summary": "Chicago, Illinois • Decatur, Illinois • Evanston, Illinois + 10 more",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Decatur",
          "state": "Illinois"
        },
        {
          "city": "Evanston",
          "state": "Illinois"
        },
        {
          "city": "Harvey",
          "state": "Illinois"
        },
        {
          "city": "Joliet",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00720174"
    },
    {
      "nct_id": "NCT02500797",
      "title": "Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Sarcoma That Cannot Be Removed by Surgery",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Locally Advanced Bone Sarcoma",
        "Locally Advanced Dedifferentiated Liposarcoma",
        "Locally Advanced Gastrointestinal Stromal Tumor",
        "Locally Advanced Soft Tissue Sarcoma",
        "Metastatic Bone Sarcoma",
        "Metastatic Liposarcoma",
        "Metastatic Soft Tissue Sarcoma",
        "Metastatic Undifferentiated Pleomorphic Sarcoma",
        "Metastatic Unresectable Sarcoma",
        "Pleomorphic Liposarcoma",
        "Stage III Bone Sarcoma AJCC v7",
        "Stage III Soft Tissue Sarcoma AJCC v7",
        "Stage IV Bone Sarcoma AJCC v7",
        "Stage IV Soft Tissue Sarcoma AJCC v7",
        "Stage IVA Bone Sarcoma AJCC v7",
        "Stage IVB Bone Sarcoma AJCC v7",
        "Unresectable Bone Sarcoma",
        "Unresectable Dedifferentiated Liposarcoma",
        "Unresectable Liposarcoma",
        "Unresectable Malignant Gastrointestinal Stromal Tumor",
        "Unresectable Soft Tissue Sarcoma"
      ],
      "interventions": [
        {
          "name": "Ipilimumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Nivolumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Quality-of-Life Assessment",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 164,
      "start_date": "2015-08-13",
      "completion_date": "2023-04-01",
      "has_results": true,
      "last_update_posted_date": "2023-10-17",
      "last_synced_at": "2026-05-22T01:40:02.716Z",
      "location_count": 651,
      "location_summary": "Anchorage, Alaska • Hot Springs, Arkansas • Little Rock, Arkansas + 402 more",
      "locations": [
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02500797"
    },
    {
      "nct_id": "NCT01653028",
      "title": "Alisertib in Treating Patients With Advanced or Metastatic Sarcoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Myxofibrosarcoma",
        "Recurrent Adult Soft Tissue Sarcoma",
        "Recurrent Leiomyosarcoma",
        "Recurrent Liposarcoma",
        "Recurrent Malignant Peripheral Nerve Sheath Tumor",
        "Recurrent Undifferentiated Pleomorphic Sarcoma",
        "Stage III Soft Tissue Sarcoma AJCC v7",
        "Stage IV Soft Tissue Sarcoma AJCC v7"
      ],
      "interventions": [
        {
          "name": "Alisertib",
          "type": "DRUG"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 72,
      "start_date": "2012-08-22",
      "completion_date": null,
      "has_results": true,
      "last_update_posted_date": "2017-11-30",
      "last_synced_at": "2026-05-22T01:40:02.716Z",
      "location_count": 235,
      "location_summary": "Scottsdale, Arizona • Aurora, Colorado • Boulder, Colorado + 153 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Boulder",
          "state": "Colorado"
        },
        {
          "city": "Boulder",
          "state": "Colorado"
        },
        {
          "city": "Colorado Springs",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01653028"
    },
    {
      "nct_id": "NCT02584309",
      "title": "Doxorubicin With Upfront Dexrazoxane for the Treatment of Advanced or Metastatic Soft Tissue Sarcoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Sarcoma, Soft Tissue",
        "Soft Tissue Sarcoma",
        "Undifferentiated Pleomorphic Sarcoma",
        "Leiomyosarcoma",
        "Liposarcoma",
        "Synovial Sarcoma",
        "Myxofibrosarcoma",
        "Angiosarcoma",
        "Fibrosarcoma",
        "Malignant Peripheral Nerve Sheath Tumor",
        "Epithelioid Sarcoma"
      ],
      "interventions": [
        {
          "name": "Dexrazoxane",
          "type": "DRUG"
        },
        {
          "name": "Doxorubicin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Washington University School of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 73,
      "start_date": "2016-02-22",
      "completion_date": "2022-07-17",
      "has_results": true,
      "last_update_posted_date": "2023-11-07",
      "last_synced_at": "2026-05-22T01:40:02.716Z",
      "location_count": 1,
      "location_summary": "St Louis, Missouri",
      "locations": [
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02584309"
    },
    {
      "nct_id": "NCT05607095",
      "title": "A Study of LN-144 or LN-145 in People With Advanced Uveal Melanoma, Undifferentiated Pleomorphic Sarcoma, or Dedifferentiated Liposarcoma",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Uveal Melanoma",
        "Melanoma",
        "Metastatic Uveal Melanoma",
        "Metastatic Melanoma"
      ],
      "interventions": [
        {
          "name": "Lifileucel (LN-144/LN-145)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Memorial Sloan Kettering Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2022-11-01",
      "completion_date": "2026-05-01",
      "has_results": false,
      "last_update_posted_date": "2026-02-04",
      "last_synced_at": "2026-05-22T01:40:02.716Z",
      "location_count": 2,
      "location_summary": "Harrison, New York • New York, New York",
      "locations": [
        {
          "city": "Harrison",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05607095"
    },
    {
      "nct_id": "NCT06789172",
      "title": "A Phase 1, First-in-human Study of OKN4395 and Pembrolizumab in Patients With Solid Tumors",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Solid Tumours",
        "Sarcoma",
        "HNSCC",
        "Non Small Cell Lung Cancer",
        "Head and Neck Squamous Cell Carcinoma",
        "NSCLC",
        "Pancreatic Adenocarcinoma",
        "Colorectal Cancer (CRC)",
        "Myxofibrosarcoma (MFS)",
        "Solitary Fibrous Tumors",
        "Dedifferentiated Liposarcoma",
        "Undifferentiated Pleomorphic Sarcoma (UPS)"
      ],
      "interventions": [
        {
          "name": "OKN4395",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "Fasting",
          "type": "OTHER"
        },
        {
          "name": "Fed",
          "type": "OTHER"
        },
        {
          "name": "H2 Receptor Antagonist",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "COMBINATION_PRODUCT",
        "OTHER"
      ],
      "sponsor": "Epkin",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 166,
      "start_date": "2025-01-23",
      "completion_date": "2028-09",
      "has_results": false,
      "last_update_posted_date": "2025-09-05",
      "last_synced_at": "2026-05-22T01:40:02.716Z",
      "location_count": 3,
      "location_summary": "Beverly Hills, California • Santa Monica, California • Houston, Texas",
      "locations": [
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Santa Monica",
          "state": "California"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06789172"
    },
    {
      "nct_id": "NCT04996004",
      "title": "A Study to Learn About the Study Medicine (Called Ontorpacept or TTI-621) Given Alone and in Combination With Doxorubicin in People With Leiomyosarcoma",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Leiomyosarcoma"
      ],
      "interventions": [
        {
          "name": "Ontorpacept (TTI-621)",
          "type": "DRUG"
        },
        {
          "name": "Doxorubicin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 76,
      "start_date": "2021-06-22",
      "completion_date": "2023-12-07",
      "has_results": true,
      "last_update_posted_date": "2024-12-11",
      "last_synced_at": "2026-05-22T01:40:02.716Z",
      "location_count": 23,
      "location_summary": "Santa Monica, California • Jacksonville, Florida • Tampa, Florida + 16 more",
      "locations": [
        {
          "city": "Santa Monica",
          "state": "California"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Iowa City",
          "state": "Iowa"
        },
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04996004"
    }
  ]
}